Home / Research Library / Pembrolizumab in combination with gemcitabine and...
🧬 Medicine & Biology OpenAlex

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

📅 April 16, 2023 👤 Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. 📖 The Lancet 📊 1,008 citations

🤖 Plain-English Summary

This research explores Pembrolizumab in combination with gemcitabine and cisplatin..., contributing new insights to the field of Medicine & Biology.

🔑 Key Findings

  • Research demonstrates significant advances in patient outcome data
  • Study provides new evidence regarding clinical efficacy results
  • Findings open new directions for biological mechanism insights

💡 Why This Matters

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

Read the full paper
Access the original peer-reviewed research via OpenAlex.

View on DOI ↗

📋 Article Details

Category 🧬 Medicine & Biology
Published Apr 16, 2023
Journal The Lancet
Authors Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn, Junji Furuse
DOI 10.1016/s0140-6736(23)00727-4
Citations 1,008
Source OpenAlex

More 🧬 Medicine & Biology Research